anti-KRAS G12D mTCR PBL
/ Gilead, National Cancer Institute - Bethesda
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 21, 2026
19-C-0017: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
(clinicaltrials.gov)
- P1/2 | N=5 | Completed | Sponsor: National Cancer Institute (NCI) | N=70 ➔ 5 | Recruiting ➔ Completed
Enrollment change • IO biomarker • Trial completion • Colon Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Rectal Cancer • Solid Tumor • ALK • EGFR • HRAS • KRAS • NRAS • PD-L1
February 10, 2022
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
(clinicaltrials.gov)
- P1/2 | N=70 | Recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Recruiting
Enrollment open • IO biomarker • Preclinical • Colon Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Rectal Cancer • Solid Tumor • ALK • EGFR • HRAS • KRAS • NRAS • PD-L1
January 26, 2021
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
(clinicaltrials.gov)
- P1/2; N=4; Suspended; Sponsor: National Cancer Institute (NCI); Active, not recruiting ➔ Suspended
IO biomarker • Trial suspension • Colon Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Rectal Cancer • Solid Tumor
January 11, 2021
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
(clinicaltrials.gov)
- P1/2; N=4; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Recruiting ➔ Active, not recruiting; N=70 ➔ 4
Enrollment change • Enrollment closed • IO biomarker • Colon Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Rectal Cancer • Solid Tumor
1 to 4
Of
4
Go to page
1